A second human glucagon-like peptide 1 (glp-1) analog/receptor agonist has been approved by the FDA for the treatment of type 2 diabetes mellitus (DM2).
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content